New Delhi: Drug firm Suven Life Sciences today said it has received a total of three product patents for CNS molecules, which could be used for treating various central nervous system disorders.The product patents -- two from Canada and one from Eurasia -- are valid through 2028, Suven Life Sciences said in a BSE filing.The company has received approval for molecules that could be used in the treatment of neuro-degenerative disorders like Parkinson, Alzheimer`s disease and Schizophrenia, it added.
Officer dies in mishap on INS Kolkata
Jagdambika Pal resigns from Congress
SC rejects Sahara`s refund proposal
Doctors` strike: Has someone from your family died? Mulayam asks mediamen